Table 3.
Changes in the “on” medications UPDRS III and UPDRS II scores.
| Score (Range) | Measures | Preoperative | One Year | Δ Change | % | ^ p |
|---|---|---|---|---|---|---|
| UPDRS III “on” (0–108) | Mean ± SD | 19.2 ± 11.7 | 12.2 ± 5.5 | −7.0 ± 9.7 | 36.5% | <0.001 * |
| Median (IQR) | 15.5 (10.3–28.1) | 11.3 (7.1–15.1) | −4.0 (−14.1–1.6) | |||
| Range | 4.0–49.0 | 5.0–27.0 | −27.0–15.0 | |||
| Tremors “on” (0–28) | Mean ± SD | 3.2 ± 4.1 | 0.7 ± 1.3 | −2.5 ± 3.8 | 78.1% | 0.002 * |
| Median (IQR) | 1.5 (0.0–5.8) | 0.0 (0.0–1.0) | −1.0 (−2.5–0.0) | |||
| Range | 0.0–14.0 | 0.0–4.0 | −13.0–0.0 | |||
| Rigidity “on” (0–20) | Mean ± SD | 2.6 ± 2.1 | 1.0 ± 1.1 | −1.6 ± 1.6 | 61.5 % | <0.001 * |
| Median (IQR) | 2.0 (1.0–4.5) | 1.0 (0.0–1.0) | −1.0 (−2.0–−1.0) | |||
| Range | 0.0–7.0 | 0.0–4.0 | −5.0–0.0 | |||
| Bradykinesia “on” (0–32) | Mean ± SD | 8.6 ± 4.6 | 6.0 ± 2.9 | −2.7 ± 3.9 | 31.4% | 0.002 * |
| Median (IQR) | 7.0 (6.0–13.0) | 5.0 (4.1–6.8) | −2.0 (−5.5–−0.6) | |||
| Range | 1.5–18.0 | 1.0–14.0 | −9.0–8.0 | |||
| Axial “on” (0–16) | Mean ± SD | 2.8 ± 1.4 | 2.5 ± 1.7 | −0.3 ± 1.4 | 10.7% | 0.046 * |
| Median (IQR) | 3.0 (1.6–3.0) | 2.0 (1.0–3.0) | −0.3 (−1.0–0.0) | |||
| Range | 1.0–6.0 | 1.0–8.0 | −2.0–5.0 | |||
| UPDRSII “on” (0–52) | Mean ± SD | 9.5 ± 5.5 | 7.8 ± 5.4 | −1.7 ± 5.5 | 17.9% | 0.073 |
| Median (IQR) | 9.0 (5.3–14.4) | 7.8 (5.3–9.5) | −0.3 (−4.9–0.0) | |||
| Range | 0.0–17.5 | 0.0–26.0 | −11.0–16.0 |
Total = 20, Δ Change from before to after (negative values indicate a reduction); p probability (p-value); SD standard deviation; UPDRS Unified Parkinson’s Disease Rating Scale; % percentage of change; ^ Wilcoxon Signed Ranks Test; * Significant.